Watch now to hear from TAVI trailblazers

Leading physicians discuss the success of TAVI treatment for their patients and what’s possible from here.

Innovating together, with 25,000+ patients studied around the world.

Scroll / swipe side to side to review timeline

Data on file, patient clinical trial enrollment data.

*The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehospitalization (valve-related or procedure-related and including heart failure) and multiple pre-specified secondary endpoints.

Learn more

Find the latest data, training programs, and resources designed to optimise patient care and increase efficiencies.

References:

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

PP--EU-4078 v1.0